Philips Lumify handheld ultrasound recalled Class I over scanning failures
The FDA logged a Class I recall of 13,206 Lumify systems on 28 October, citing software that can block scanning without network access and unstable transducer connections that may delay diagnosis or treatment.
The Food and Drug Administration has recorded a Class I recall of the Philips Lumify Diagnostic Ultrasound System, a handheld scanner, after identifying two faults that can stop it working when it is needed [s1]. The agency logged the enforcement report on 28 October 2026 and assigned it the most serious recall classification, the tier reserved for defects that could cause serious injury or death [s1].
Lumify is a portable ultrasound: a transducer probe that plugs into a tablet or phone, designed for use at the bedside and beyond the hospital. That mobility is exactly what the recall puts at issue.
What can go wrong
The enforcement record describes two failure modes [s1]. In the first, the system may not recognise a transducer's previous registration and refuse to scan, demanding re-registration that requires Wi-Fi or cellular access [s1]. The record is blunt about where that leaves a clinician: such connectivity "may be unavailable outside of the hospital" — in ambulances, aircraft or the field [s1]. A scanner that will not turn on without a network connection is of little use in precisely the mobile settings it was built for.
In the second, the connection between the transducer's USB cable and the tablet or phone may be unstable and can disconnect, disrupting the device's function [s1]. Either fault, the FDA notes, may cause a delay in diagnosis or treatment [s1].
No clotting or bleeding is at stake here, as with a recalled drug; the harm is the harm of a diagnostic tool that fails mid-use. In acute care, a delay in imaging a patient — to check for internal bleeding, a collapsed lung or a failing heart — can itself be the injury.
What is affected
The recall covers 13,206 systems distributed worldwide, including nationwide across the United States and into dozens of other countries [s1]. The affected products span specific software versions on both platforms the app runs on: Android versions 1.X, 3.X, 4.X and 5.X, and iOS versions 2.X and 5.X, identified in the record by their device identifiers [s1].
Philips Ultrasound, LLC began the action itself, and the FDA records it as a voluntary, firm-initiated recall [s1]. The firm initiated it on 24 September 2026; the agency's device centre classified it on 16 October and logged the enforcement report on 28 October, so the public record of how serious the defect is reached the database a little over a month after the firm first acted [s1]. The recall's status is ongoing [s1].
Why a software fault draws the top tier
It can seem surprising that a connectivity glitch rather than a physical defect earns the FDA's most serious classification. But the classification turns on potential consequence, not on how dramatic the fault looks. A diagnostic device that becomes unavailable at the point of care — especially one marketed for ambulances and remote settings where no backup scanner is at hand — fits the agency's definition of a defect that could lead to serious harm, because the missed or delayed diagnosis is the danger [s1]. The record documents the defect and the recall, not any specific patient harm [s1].
What to watch
Because the action is ongoing, the practical questions are whether Philips's fix — a software update or re-registration process that does not depend on being online — reaches every affected unit, and whether the correction removes the network dependency that makes the first fault so consequential in the field [s1]. Facilities and clinicians relying on Lumify should follow the manufacturer's recall instructions to confirm whether their software version is among those listed, rather than assume a given unit is unaffected.
This article describes a regulatory enforcement action and is not medical advice.
Sources
- FDA Enforcement Report Z-0152-2027: Philips Lumify Diagnostic Ultrasound System — U.S. Food and Drug Administration (openFDA device/enforcement API) , October 28, 2026
Medline homecare beds recalled Class I over hand-control fire hazard
The FDA logged the most serious recall tier on 7 October for Medline Basic and Medlite homecare beds, whose hand-control pendant and wiring can overheat and may smoke, spark, melt or catch fire.
Ventec recalls ventilators in Class I action over a connector that can reboot them
The FDA logged a Class I recall of Ventec's VOCSN, V+Pro, VC and V*Home ventilators on 28 October, citing an internal cable connector that can detach, rebooting the device and interrupting breathing support.
Class I recall hits a hospital test for a dangerous clotting reaction
The FDA logged a Class I recall of Instrumentation Laboratory's HemosIL AcuStar HIT assay on 21 October. Certain lots can read up to 47% low, risking a missed diagnosis of heparin-induced thrombocytopenia.
Penumbra recalls a stroke-clot catheter that can fracture during use
The FDA logged the recall of the RED 62 reperfusion catheter, part of the Penumbra System used to pull clots from the brain, on 7 October. Manufacturing problems mean the device may fracture; 43 units are affected.